Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Papillomavirus Infections 2Neoplasms 2Liver Neoplasms 2Liver Diseases 2Carcinoma, Hepatocellular 2Virus Diseases 1Stomach Neoplasms 1Rheumatic Diseases 1Primary Graft Dysfunction 1Liver Failure, Acute 1Liver Failure 1HIV Infections 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Adenocarcinoma 1

Interventions

Gemcitabine 7Leucovorin 6Irinotecan 6Fluorouracil 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Capecitabine 4Paclitaxel 3Oxaliplatin 3Ocoxin 3Bevacizumab 3pembrolizumab 2entinostat 2Sorafenib 2Imatinib Mesylate 2Everolimus 2Cyclophosphamide 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2tislelizumab 1spartalizumab 1pralsetinib 1palbociclib 1irinotecan sucrosofate 1halofantrine 1guadecitabine 1fludarabine 1ficlatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Digestive System Neoplasms × halofantrine × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡